The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for game-changing treatments and significant returns is undeniable, the associated risks are also sign… Read More